Saralasin in human hypertension: the early experience.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000804:Angiotensin II / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000378:metabolism; D001667:Binding, Competitive; D001794:Blood Pressure / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D006973:Hypertension / Q000209:etiology / Q000378:metabolism*; D006974:Hypertension, Malignant / Q000378:metabolism / Q000503:physiopathology; D006977:Hypertension, Renal / Q000378:metabolism / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009318:Natriuresis / Q000187:drug effects; D011187:Posture; D012083:Renin / Q000097:blood / Q000378:metabolism; D012504:Saralasin / Q000378:metabolism* / Q000494:pharmacology; D012964:Sodium / Q000378:metabolism; D013997:Time Factors; D014661:Vasoconstriction / Q000187:drug effects
D000804:Angiotensin II; D012964:Sodium; D012083:Renin; D012504:Saralasin